Eli Lilly 2007 Annual Report Download - page 9

Download and view the complete annual report

Please find page 9 of the 2007 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 132

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132

PORTFOLIO AND PIPELINE
7
1995 ReoPro® for prevention of cardiac ischemic complications in patients undergoing
coronary intervention, such as angioplasty
for unstable angina associated with stent procedure (1997)
(in collaboration with Centocor, except in Japan)
1987 Humatrope® for growth failure caused by pediatric growth hormone defi ciency
for replacement therapy for adult growth hormone defi ciency (1995)
for short stature caused by Turner syndrome (1997)
for idiopathic short stature (2003)
1983 Humulin® for type 1 and type 2 diabetes
New Drug Applications Submitted For Review to the U.S. Food and Drug Administration
Duloxetine for fi bromyalgia
Olanzapine for adolescent schizophrenia and bipolar disorder
Olanzapine LAI long-acting injection delivery for schizophrenia
Olanzapine-Fluoxetine for treatment-resistant depression
Pemetrexed disodium for fi rst-line treatment of non-small-cell lung cancer
Prasugrel for prevention/reduction of atherothrombotic events in patients with acute coronary
syndromes who undergo percutaneous coronary intervention (PCI)
(in collaboration with Daiichi Sankyo Company, Ltd.)
Ruboxistaurin mesylate for diabetic retinopathy
Teriparatide (rDNA origin) for glucocorticoid-induced osteoporosis (GIOP)
injection
Select Drug Candidates in Late-Stage Investigation
Arzoxifene for the prevention and treatment of osteoporosis and breast cancer risk reduction
AIR® Inhaled insulin for type 1 and type 2 diabetes
(in collaboration with Alkermes, Inc.)
Duloxetine for chronic pain
Enzastaurin for poor prognosis patients with diffuse large B-cell lymphoma
Exenatide for once-weekly dosing
MBP8208 for secondary progressive multiple sclerosis (SPMS) and relapsing-remitting multiple
sclerosis (RRMS)
(in collaboration with BioMS Medical Corp.)
Teplizumab for type 1 diabetes
(in collaboration with MacroGenics)
(continued next page)